skip to main content

SGLT2i Benefit Low Albuminuria Mechanism — ESENeph MCQ

Instant feedback + full explanation. One question, done properly.

ModerateChronic Kidney DiseaseSGLT2i Benefit Low Albuminuria MechanismESENeph

A 48-year-old woman with CKD G3a from membranous nephropathy in remission develops new-onset diabetes. She is started on Metformin and Dapagliflozin. Her eGFR is 55 and uACR is 3 mg/mmol (A1). Six months later, her eGFR is 57 and uACR is 1.5 mg/mmol. Is the SGLT2i providing renal benefit despite minimal albuminuria?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: A — Yes – SGLT2i provides renal benefit through haemodynamic mechanisms (reducing intraglomerular pressure) independent of baseline albuminuria level; the stabilised eGFR and reduced albuminuria support ongoing benefit

SGLT2i renoprotective mechanisms are primarily haemodynamic (afferent arteriolar vasoconstriction via tubuloglomerular feedback) and anti-inflammatory/anti-fibrotic, not dependent on baseline albuminuria. EMPA-KIDNEY showed benefit even in patients with ACR <30 mg/mmol. The stabilised eGFR and reduced uACR confirm ongoing benefit. Additional mechanisms include reduced oxidative stress, improved tubular oxygenation, reduced inflammation, and metabolic effects. These mechanisms operate regardless of baseline proteinuria level.

Reference: KDIGO 2024 – CKD; Heerspink et al 2020 – SGLT2i Mechanisms